therascreen® KRAS RGQ PCR Kit by QIAGEN

The therascreen® KRAS RGQ PCR Kit is intended to detect 7 mutations in codons 12 and 13 of the KRAS gene. The kit utilizes two technologies — ARMS and Scorpions — for detection of mutations in real-time PCR. The therascreen KRAS RGQ PCR Kit is an FDA-approved, qualitative real-time PCR assay for the detection of specific mutations in the KRAS oncogene. The kit provides reagents optimized for rapid and sensitive detection of 7 somatic mutations using the Rotor-Gene Q MDx instrument. The therascreen KRAS RGQ PCR Kit enables the detection of 7 mutations in codons 12 and 13 of the human KRAS gene using DNA extracted from formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) tissue samples. The therascreen KRAS RGQ PCR Kit is only intended to discriminate between KRAS mutation-negative (wild-type) and KRAS mutant tumors. Features: FDA-approved for in vitro diagnostic use Standardized assay for reproducible results Ready-to-use system with simple workflow Specific and sensitive due to ARMS and Scorpions PCR technologies KRAS mutations detected by the therascreen KRAS RGQ PCR Kit include: 12ALA 12ASP 12ARG 12CYS 12SER 12VAL 13ASP
QIAGEN Product Finder
QIAGEN Online shopping guide